GSK-J4 combined with mitomycin C as a novel combination therapy for non-muscle invasive bladder cancer

Caridis, Anna-Maria; Perkins, Callum; Maio, Alessandro Di; Ward, Douglas G.; Oppermann, Udo; Bountra, C.; Khanim, Farhat L.; Bryan, Richard T.

doi:10.3389/conf.fonc.2019.01.00010

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Developments in technology for genomic analyses have identified molecular subtypes of NMIBC, potentially permitting the future stratification of BCa treatments and the subsequent delivery of personalised intravesical therapeutic approaches in the management of NMIBC ( 12 ). Although such precision medicine in NMIBC has not yet been realised, several drugs that target and “reset” genome-wide epigenetic modifications are being investigated in pre-clinical studies, and have shown extremely promising results in pre-clinical BCa models ( 129 , 130 ).…”

Section: Discussionmentioning

confidence: 99%

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning

et al. 2022

View full text Add to dashboard Cite

IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease. Intravesical drug therapy is a pillar in the current management of NMIBC; notwithstanding, Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) have numerous limitations including international supply issues, and local and systemic toxicity. Here we review novel intravesical therapeutic options and drug delivery devices with potential for clinical use in the treatment of NMIBC.MethodsPubMed, ClinicalTrials.gov and Cochrane Library searches were undertaken. Systematic reviews, meta-analyses, randomised controlled trials, single-arm clinical trials and national/international conference proceedings were included.ResultsNovel intravesical drugs, including chemotherapeutic agents, immune checkpoint inhibitors, monoclonal antibodies and gene therapies, have demonstrated varying efficacy in the treatment of NMIBC. Current evidence for the majority of treatments is mostly limited to single-arm trials in patients with recurrent NMIBC. Various novel methods of drug delivery have also been investigated, with encouraging preliminary results supporting the intravesical delivery of hyperthermic MMC and MMC hydrogel formulations.ConclusionsNovel therapeutic agents and drug delivery systems will be important in the future intravesical management of NMIBC. As our understanding of the molecular diversity of NMIBC develops, molecular subtyping will become fundamental in the personalisation of intravesical treatments. Further randomised studies are urgently required to investigate the efficacy of novel intravesical treatments and novel regimens, in comparison to current standards-of-care, particularly in the context of international BCG shortages.

show abstract

Section: Discussionmentioning

confidence: 99%